Rubrika: Výzkum

Aktuální informace společnosti Roche/Genentech o studii GENERATION HD2

Roche/ Genentech announce that Phase II GENERATION HD2 study is now open. This is great news for the international community since it is planned to run in 15 countries (Argentina, […]

Společnost Novartis ukončuje studii VIBRANT-HD

Novartis shared today the difficult news that they are stopping the VIBRANT-HD study of Branaplam, after some participants devoloping side effects. Read the full Novartis letter Even if this news […]

Společnost uniQure oznámila, že obnovuje nábor pacientů do studie AMT-130 ve vyšších dávkách.

A Message to the Huntington’s Disease Community from uniQure Dear Huntington’s Disease Community Members, This morning, uniQure issued a press release which included an update on our clinical trial ofAMT-130 […]

Společnost Wave Life Sciences oznamuje pozitivní výsledky studie fáze 1b/2a SELECT-HD s prvními výsledky naznačujícími selektivní zapojení alel do cílové skupiny pomocí WVE-003 u Huntingtonovy choroby

September 20, 2022 at 7:30 AM EDT PDF Version Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 […]

Společnost uniQure oznamuje aktualizované informace o kohortě s nízkými dávkami v klinické studii fáze I/II genové terapie AMT-130 pro léčbu Huntingtonovy choroby

~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~ ~ A mean reduction of 53.8% of mutant HTT […]

Společnost Annexon Biosciences aktualizuje výsledky studie

ANNEXON BIOSCIENCES REPORTS PHASE 2 CLINICAL TRIAL RESULTS DEMONSTRATING UPSTREAM CLASSICAL COMPLEMENT INHIBITION ASSOCIATED WITH CLINICAL BENEFIT IN HUNTINGTON’S DISEASE On June 7, Annexon, that is a clinical-stage biopharmaceutical company […]

Webinář - Vše, co potřebujete vědět o technologii Proof-HD

Yesterday, Prilenia hosted a webinar updating on the Phase III trial with Pridopidine. Thank you to everyone who join and a special thanks to our speakers, Michael Hayden, Andrew Feigin, […]

Přelomové zprávy - Roche plánuje novou studii Tominersenu

Some encouraging news has just come in from Roche.  Analysis of the results of Roche’s Phase III GENERATION HD1 trial, which was stopped in March 2021, has found that a […]